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 Acute kidney injury (AKI) as a conse-
quence of ischemia is a common clinical 
event that leads to high morbidity and mor-
tality. Ischemia / reperfusion injury (IRI) 
is also the main cause of delayed graft  
func tion in recipients of renal allograft s 
from deceased donors. 1 Th is problem 
with delayed graft  function is more oft en 
seen in the era of extended-criteria kidney 
donors. Th ere is currently no specifi c ther-
apy to either treat IRI or accelerate healing 
of the kidney. Homeostasis in the immune 
system is dependent on a balance between 
responses that control infection and in-
jury, and the reciprocal responses that 
prevent infl ammation and autoimmune 
diseases. Earlier studies have shown that 
T lymphocytes have a role in the patho-
genesis of renal IRI. 2,3 Lymphocytes, 
particularly CD4   +   T cells, have been found 
to directly mediate AKI as well as IRI 
injury to the liver, lung, and intestine. 
Lymphocytes have also been implicated in 
the pathogenesis of cardiac ischemia and 
stroke. Th e recognition of this important 
fi nd ing was delayed by limited data on 
early lymphocyte infi ltration soon aft er 
kidney injury. Furthermore, there is no 
con ceptual model to explain how lympho-
cytes could be involved in acute, alloanti-
gen-independent, tissue injury. 
 It is now well established that the com-
mon pathway in the pathophysiology of 
AKI is an infl ammatory process with close 
interaction between many cell types. In 
the recovery phase, diff erent T lymphocyte 
sub-populations could also be involved in 
promoting damage or in enhancing repair. 
Th is is even more interesting in the clini-
cal setting of organ transplantation with 
increased incidence of acute allograft 
rejection associated with delayed graft  
function. Again, infl ammation seems to 
be the common factor that links the vari-
ous cell types involved in this process. Th is 
early and transient T-cell infi ltration can 
be blocked by a sphingosine-1-phosphate 
receptor type 1 (S1P1)-selective agonist. 4 
Regulatory T cells (Tregs) play a critical 
role in suppressing immune responses to 
injury. Furthermore, blocking of Tregs 
worsens AKI, and infusion of Tregs 
protects against AKI caused by IRI, and 
nephrotoxic agents such as cisplatin. 5 
 In a murine model of ischemic AKI, a 
significant trafficking of Tregs into the 
kidney was found within the first 
week. Specifi cally, Tregs infi ltrate ischemic 
reperfused kidneys during the healing 
process to promote repair. Treg depletion 
worsened mortality and renal function, 
whereas Treg infusion had a beneficial 
eff ect on renal function. For this reason, 
Treg targeting was considered as a new 
therapeutic approach to enhance recovery 
from ischemic AKI. Direct infusion of 
Tregs as a form of cellular therapy has been 
shown to have potential in treating or pre-
venting a number of experimental auto-
immune diseases. Diff erent strategies for 
isolation and enrichment of Tregs have 
been attempted clinically, with limited suc-
cess. Th e main obstacle is related to the low 
frequency of Tregs in the peripheral blood 
and the need for  ex vivo multiplication of 
the cells prior to their use  in vivo . 6,7 
 In organ transplantation, Treg therapy 
has been demonstrated experimentally in 
adoptive transfer models. A large number 
of Tregs are required, so Treg therapy alone 
may not be suffi  cient for tolerance induc-
tion. At present, immunosuppressive drugs 
are still the mainstay of the maintenance of 
graft  survival following transplantation. 
Ideally, these drugs should inhibit eff ector-
cell functions while maintaining or 
enhancing Treg activity to improve out-
comes in clinical transplantation. Th era-
peutic administration of Tregs alone is not 
likely to prevent graft  rejection. Applica-
tion of Treg therapy in clinical settings 
will require a better understanding of 
Treg behavior  in vivo in transplant patients 
with maintenance immunosuppression. 8,9 
Better choices of different immuno-
suppressive agents will have an eff ect on 
the fostering of Treg diff erentiation. 
 Lai  et al. 10 (this issue) now demonstrate 
an alternative approach of using a pharma-
ceutical agent  in vivo to stimulate Tregs 
to achieve immunosuppressive effect 
( Figure 1 ). Specifi cally, a naturally occurring 
sphingosine derivative,  N , N -dimethylsphin-
gosine (DMS), was used to recruit Tregs to 
the kidney. DMS is a known sphingosine 
kinase inhibitor. An increase in CD4   +   , 
Foxp3   +   Tregs in the kidney was associated 
with attenuation of renal injury to the kid-
ney if given before ischemia. Th is renopro-
tective eff ect was diminished by anti-CD25 
and anti-CTLA-4 antibodies, indicating 
the critical role of Tregs. Th is approach is 
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 Lai and colleagues demonstrate that pretreatment with  N , N -dimethyl-
sphingosine (DMS), a naturally occurring sphingosine derivative, 
provides renoprotection in ischemia / reperfusion injury. This DMS-
induced renoprotection was abolished by the administration of agents 
that suppress regulatory T cells (Tregs) or by anti-CTLA-4 or anti-CD45 
monoclonal antibodies, suggesting that Tregs played a critical role. 
The finding that Tregs are recruited to the kidney via DMS points to 
the exciting potential of new approaches to harnessing Tregs for 
therapeutic purposes. 
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unique and might have important clinical 
implications. The effect of DMS in Treg 
recruitment appears to be short term, with 
suppression of undesired inflammatory 
reaction without long-term immuno-
suppression eff ect. Current studies focus 
on the prevention of initial injury, and pre-
treatment seems to be necessary for the 
beneficial effect to take place. Such an 
approach would limit the use of the agent in 
organ preservation or in the prevention of 
IRI that may occur during a cardiac surgery 
procedure. 
 On the basis of this study, the increase 
of Tregs by DMS most likely occurs by 
trafficking of existing Tregs, because 
CD4   +   T cells and CD4   +   Foxp3   +   Tregs 
peak at 1  h after DMS treatment and 
DMS upregulates the renal expression of 
CCL5, CXCL9, and CXCL10. Th is process 
may trigger the common chemotactic 
mechanism shared by both eff ective and 
regulatory T cells, as DMS has been shown 
to exert multiple biological functions, 
such as inhibiting protein kinase C, acti-
vating sphingosine-dependent protein 
kinase 1, and mobilizing calcium, which 
may also contribute to Treg traffi  cking to 
the kidney. The exact mechanism and 
pathway of this pharmacological approach 
to enhancing Tregs still require further 
clarifi cation. 11 
 The exact balance between effector 
and regulatory T cells is important for the 
maintenance of self-tolerance and of func-
tional immune responses. Tregs mediate 
suppressive eff ects by several mechanisms, 
including anti-infl ammatory cytokines 
(interleukin-10, transforming growth fac-
tor-  , and interleukin-35), metabolic 
modulation (adenosine production and 
interleukin-2 deprivation), direct cyto-
toxicity (granzyme B and galectin-1), and 
dendritic-cell function (CTLA-4, LAG3, 
and IDO induction). Th e eff ect of DMS on 
this delicate balance needs further elucida-
tion. It is now fi rmly established that there 
are both natural (or constitutive) and 
inducible (or adaptive) populations of 
Tregs, which may have complementary 
and overlapping functions in the control 
of immune responses: thymic-derived 
naturally occurring CD25   +   CD4   +   cells 
(nTregs) and induced or adaptive Tregs 
(iTregs) that are either diff erentiated from 
CD25  –  CD4   +   non-regulatory cells or 
expanded from CD25   +   CD4   +   cells in 
response to antigen. Th ese cells diff er in 
origin, antigen experience, methylation 
patterns of the key transcription factor 
Foxp3, and suppressive mecha nisms. Two 
broad options for Treg therapy can there-
fore be exploited, namely, induction of 
Tregs from naive precursors  in vivo and 
infusion of autologous Tregs expanded 
from peripheral blood  ex vivo . Th e possi-
bility of using pharmaceutical recruitment 
of Tregs is encouraging and raises the 
possibility of using other specifi c agents in 
accomplishing this goal. 
 One fi nal important note is that human 
Tregs are currently less well characterized 
and understood than mouse Tregs. Th ere-
fore, a thorough understanding of their 
biology is vital before clinical application 
can be initiated with any pharmacological 
manipulation. 
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 Figure 1  |  Two broad approaches are available to recruit Tregs for therapeutic purposes. 
The first is to expand Tregs  in vitro first and then apply expanded Tregs as a cell therapy  in vivo . 
The advantage of this approach is that antigen-specific Tregs can be created  in vitro with the use 
of donor-specific antigen. The second approach is to selectively and specifically stimulate Tregs 
 in vivo by using pharmacological agents. This is accomplished by taking advantage of fundamental 
differences in the biology of Tregs and effector T cells. Treg, regulatory T cell. 
